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ABSTRACT
ELEVATION OF CARDIAC GLYCOLYSIS REDUCES PYRUVATE
DEHYDROGENASE BUT INCREASES GLUCOSE OXIDATION
Qianwen Wang
April 1, 2011
Heart failure is the most frequent cause of mortality in western countries. Currently,
there is no cure treatment for heart failure and the long term survival rate following heart
failure is poor, with one third of patients dying within a year of diagnosis. Thus, new
therapeutic targets have to be developed.
Enhanced glycolysis is a very common phenomenon in the development of heart
failure and maybe a target for drug development. However it is not know whether the
increased glycolysis is a cause or an effect of heart failure. Also, metabolic modulators to
increase glucose use by the heart have been used acutely in treatment in heart failure but
the long term impact of increased glycolysis is not known. To understand whether
chronically increased glycolysis specifically in the heart is beneficial or detrimental,
glycolysis was chronically elevated by cardiac-specific overexpression of a modified,
phosphatase-deficient 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2) in
transgenic mice. PFK-2 controls the level offructose-2, 6-bisphosphate (Fru-2, 6-P2 ), an
important regulator of phosphofructokinase and glycolysis. These transgenic mice were
used to test two hypotheses: (1) Long term elevation of cardiac Fru-2, 6-P 2 will increase
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glycolysis and alter glucose oxidation. (2) Chronically increased cardiac glycolysis will
be detrimental to the heart.
To test these hypotheses we carried out three specific aims: Aim I was to produce
transgenic mice with overexpression of phosphatase-deficient 6-phosphofructo-2kinase/fructose-2, 6-bisphosphatase (PFK-2). Aim 2 was to compare metabolites and
glucose metabolism in transgenic and control samples using whole hearts, Langendorff
perfused hearts and cultured adult cardiomyocytes. Aim 3 was to assess whether
chronically increased glycolysis promotes cardiac fibrosis, hypertrophy or impaired
function.
The results demonstrated a new line of transgenic mice called Mk, with cardiac
expression of modified PFK2 and increased levels ofFru-2, 6-P 2. Mk hearts had elevated
glycolysis that was less sensitive to inhibition by palmitate. Mk cardiomyocytes had
increased glucose oxidation despite reduced pyruvate dehydrogenase complex (PDC)
activity. PDC activity was decreased because of reduced protein levels of PDC subunit
Ela and because of increased PDC Ela phosphorylation. Mk hearts had increased
mitochondrial level of MCT -2 transporter protein and malate content. The increased
malate content and elevated MCT2 expression suggested that anaplerosis pathways in
transgenic hearts might explain the paradoxical finding of reduced PDC activity and
elevated glucose oxidation.
Functional studies revealed that the elevation in glycolysis made transgenic
cardiomyocytes highly resistant to contractile inhibition by hypoxia, in vitro. However, in

vivo the trans gene had no protective effects on ischemia-reperfusion injury. Furthermore,
the transgenic hearts exhibited pathologic changes that included a 17% increase of the
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heart weight-to-body weight ratio, greater cardiomyocyte length and increased cardiac
fibrosis. Therefore, chronic elevation of glycolysis produced more pathological effects
than protective effects on the heart.
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INTRODUCTION

Significance and Background

Heart failure, the most frequent cause of mortality in the western countries, is more
prevalent than all cancers combined (71). Currently, no cure treatment for heart failure is
available, and the long term survival rate following heart failure is poor, with one third of
patients dying within a year of diagnosis (10). Thus, studies, focusing on identifying new
therapeutic targets to prevent or reverse cardiac hypertrophy from the transition to heart
failure, have to be developed.
In the development of heart failure, cardiac hypertrophy serves as an important risk
factor and is explained largely by an increase in cardiac myocyte size due to pathological
overload. In addition to structural changes in the myocardium, an altered utilization of
cardiac metabolic substrate glucose is recognized as one of the biochemical hallmarks of
the hypertrophied and failing heart (42). In the fetal heart, glucose is the primary cardiac
substrate while fatty acid metabolism is reduced due to carnitine deficiency and delayed
maturation of enzymes involved in fatty acid oxidation. In the healthy heart under resting
conditions, the oxidation of fatty acid covers about 70% of the cardiac energy demand,
with additional significant contributions from glucose and lactate (Figure 1). During the
normal physiological growth of the heart including pregnancy-induced growth and
exercise-induce cardiac hypertrophy, glucose utilization (includes glycolysis and glucose
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oxidation) and fatty acid oxidation are enhanced. However, in the development of
pathological cardiac hypertrophy and heart failure, fatty acid oxidation decreases,
glycolysis increases while glucose oxidation varies (increases, decreases or no change)
(10). Elevated glycolysis is considered to be an adaptive response to compensate for the
reduced energy efficiency of the compromised heart (53). On the other hand, rather than
being an adaptive response, elevation of cardiac glucose metabolism may be an example
of the prominent reversion to fetal gene expression that occurs during heart failure (76).
Decoupling of the rate of glucose oxidation from the rate of glycolysis has been
demonstrated in experimental models of heart failure, and this is potentially detrimental
to long term cardiac function (49). However it is not certain whether decoupling is a
direct consequence of elevated glycolyisis, or it occurs only in the context of heart
failure.
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Diabetes Reduces Glycolysis

Diabetes is one of the major risk factors in the development of heart failure, and
diabetes has major effects on cardiac fuel metabolism. In the normal heart the rate of
glycolysis is responsive to changing metabolic demand (8). In diabetes there is a marked
reduction in the ability of the cardiac myocyte (75) to accelerate glycolytic rate due to
decreased glycolytic capacity. This reduction in cardiac glucose usage is found both in
the hearts of diabetic patients (4, 14, 80) and in experimental models of diabetes (75).
Metabolic flux analysis (37) demonstrates that control of cardiac glycolysis is not limited
to a single metabolic step; rather it is shared by several reactions, depending on ambient
conditions. In the diabetic myocyte there is decreased activity in several critical steps of
the glycolytic pathway ensuring that overall rate of glycolysis is impaired. Activity of
glucose transporters (75), hexokinase (17), 6-phosphofructo-1-kinase (PFK) (55) and
glyceraldehyde-3-phosphate dehydrogenase (19) all decline in diabetes. Mechanisms for
reduced enzyme activity are multiple but include reduced gene expression for glucose
transporters and hexokinase (12, 22) and elevated concentrations of metabolic inhibitors
for hexokinase (15) glyceraldehyde-3-phosphate dehydrogenase and PFK (16).
In addition to reduced glucose usage, diabetic hearts also display an abnormally large
reliance on fatty acid oxidation for energy. It has been proposed that this contributes to
the development of diabetic cardiomyopathy (68). Fatty acids are the major source of
fuel in the normal heart. But in diabetes this reliance is exaggerated. In part this is due to
elevated circulating lipids. But it also appears to be a function of decreased glucose
metabolism. Glucose metabolism produces increased intracellular levels of malonyl CoA
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(5), a potent inhibitor of fatty acid conjugation to camitine. This step is a major control
point for movement of fatty acids into the mitochondria for oxidation. With reduced
glucose metabolism, one of the normal braking systems for oxidation of lipids is lost.

Reduced Glycolysis and Diabetes Increase Vulnerability to Ischemic Damage

The reduced glycolytic activity of the diabetic heart is an important factor that
predisposes to ischemic or hypoxic damage. In ischemic (54) hearts, dependence on
glucose and glycolysis increases markedly. One of the protective responses of the heart is
an increase in glycolysis (69, 74). In fact, stimulation of glycolysis with glucose and
insulin has been used for many decades to protect patient hearts from ischemic or
hypoxic damage (60,61). In vitro experiments analyzing glycolysis and ischemia support
this clinical practice. Studies in isolated perfused hearts reveal that manipulations to
accelerate cardiac glucose use decrease ischemic damage (62, 83) while procedures that
limit glycolysis tend to sensitize the heart to ischemia (31). In one of the genetic
modification studies in this area, Tian et aI., (78) found that cardiac specific knockout of
the GLUT4 glucose transporter, a mutation that reduces cardiac glycolysis, sensitizes the
heart to hypoxic damage. They proposed that the damage was similar to the damage seen
in diabetic hearts. It is also established that one protective response of the heart to
ischemic stress is a significant increase in glycolysis.
Diabetes reduces glycolysis, and studies of diabetic models reveal exacerbated
ischemic damage that confirm the outcome found in diabetic patients. However, certain
experimental variables can alter this outcome. The enhanced sensitivity of the heart is
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most apparent when the diabetes is of long duration (66). Also, the diabetic deficit may
be hidden if it is tested following complete blockage of flow. This is thought to be a
function of lactate buildup in normal hearts (20, 38) which occurs during complete
obstruction of flow. Diabetic hearts are protected from lactate build up by their lower
rates of glycolysis (20, 38). Studies that use chronic models of diabetes and reduced
flow, rather than zero flow ischemia find that diabetes increases ischemic damage (66).
The mechanism of glucose induced cardiac protection in ischemia has not been
resolved. However, it is clear that glycolysis becomes the sole or primary source of ATP
production in hypoxic hearts.

Also, ATP derived from glycolysis seems to have a

preferential role (85) in maintaining normal conductances for calcium, potassium and
sodium ions, functions that are critical in maintaining cardiac myocytes viability during
ischemia. Glycolytic enzymes are located in close proximity to the ATP dependent
sarcoplasmic reticulum calium pump (90) and the ATP regulated potassium channel(86).
Active glycolysis has been shown to be critical in the activity of the sarcoplasmic calcium
pump (90) and the ATP-sensitive potassium channel (86).

Reduced Glycolysis Predisposes to Cardiomyopathy

Genetic mutations, whether natural (3) or experimental (77), that impair glycolysis
produce cardiac pathology. The most prominent finding in glucose transporter (GLUT4)
knockout mice is cardiac hypertrophy (77). When additional knockout mice were made
in which cre-IoxP technology was used to confine the GLUT4 knockout to the heart,
cardiac hypertrophy was still observed (1). These results indicate that chronic impaired
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glucose metabolism promotes cardiac damage.

Conversely it appears that enhanced

glycolysis may prevent diabetic cardiomyopathy. A report by Belke et at, described the
effect of overexpression of the GLUT4 glucose transporter on diabetic cardiomyopathy in
(7). They found that db/db mice with a glucose transporter transgene had markedly
improved cardiac contractility compared to nontransgenic db/db mice.

However,

conclusions based on this exciting result must be tempered by the fact that the glucose
transporter trans gene was active in many tissues.

Cardiac protection may have been

secondary to extra-cardiac actions of the trans gene, such as reductions in blood glucose
levels (23).
A number of findings from non-genetic studies support the hypothesis that altered
glucose metabolism can contribute to cardiomyopathy. Apoptosis of cardiac myocytes,
which is known to occur during heart failure (52), is inhibited by manipulations that
increase glycolysis (50). Bishop and Altrud (ll)reported 30 years ago that glycolytic
metabolism is increased in cardiac hypertrophy and congestive heart failure. This may be
an adaptive mechanism to take advantage of the higher yield of ATP from carbohydrate
metabolism. Studies utilizing in vitro application of inhibitors of glucose metabolism,
such as 2-deoxyglucose report weakened contractility, even under well-oxygenated
conditions (36). Notably, the most prominent finding described was impaired diastolic
relaxation, which is also the most prominent defect in diabetic cardiomyopathy (73).
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Therapeutic Implications

Traditional clinic treatment of heart failure involves management of risk factors and
control of symptoms by using angiotensin converting enzyme inhibitors, angiotensin
receptor blockers, beta blockers, diuretics, aldosterone antagonists and digitalis.
However, these classic agents for treating heart failure have direct hemodynamic,
inotropic or chronotropic effects, with significant potential for morbidity and mortality.
Recently, metabolic modulators, such as trimetazidine, ranolizine, perhexiline and
estomoxir, and other drugs have been developed as a new class of drugs that may act by
shifting substrate utilization from fatty acid to glucose utilization, either directly through
stimulation of glycolysis or indirectly through inhibition of fatty acid oxidation
(63).Under normal physiological conditions, oxidation of fatty acid can yield higher ATP
amounts compared with the oxidation of glucose (129 A TP per palmitate molecule versus
36 ATP per glucose molecule). However, in terms of oxygen cost, the oxidation of
glucose is more efficient

(ATP/O~3.1)

than that of fatty acid

(ATP/O~2.8).

This means

that switching from fatty acid utilization toward glucose oxidation is approximately 11 %
more economical in terms of oxygen cost in the heart (81). Therefore, the fact that
metabolic modulators can shift the heart to use more glucose is thought to be beneficial.
However, all these metabolic modulators are only acutely used in treatment in heart
failure and the impact of increased glycolysis by this class of drugs on overall mortality
for the long term use is still under investigation. (63) In order to reveal long term effects
of increased cardiac glucose utilization on heart, a transgenic mice model (Mk) with
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chronically cardiac specific increased glycolysis by overexpression of kinase active PFK2 was established.

PFK-l trans gene and Transgenic mice

The control of cardiac glycolysis is shared by several reactions (37). One of the
control reactions is carried out by 6-phosphofructo-l-kinase (PFK-l) (29, 55), which
catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-l ,6-bisphosphate
(Fru-l,6-P2). F6P is in equilibrium with glucose-6-phosphate (G6P), and these two sugars
initiate glycogen synthesis, the hexosamine pathway, and the hexose monophosphate
shunt. Thus, PFK-l not only has an important role in regulating glycolysis but, by
controlling the metabolism ofF6P, PFK-l can also modulate several important reactions
branching off of glycolysis. PFK-I activity is tightly controlled and negatively regulated
by products of fat metabolism, including A TP and citrate. The most important positive
regulator ofPFK-1 is fructose-2, 6-bisphosphate (Fru-2, 6-P 2). The bifunctional enzyme
6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2) catalyses the synthesis
and degradation of Fm-2, 6-P2. PFK-2 is, in tum, regulated by a complex network of
kinases, phosphatases, and metabolites (59). In this study, we used a cardiac-specific
trans gene for a mutant form of liver PFK-2 to directly elevate cardiac Fru-2, 6-P2 and
increase glycolysis without inducing heart failure.
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Hypothesis and Aims
To understand whether chronically increased glycolysis specifically in the heart is
beneficial or detrimental, glycolysis was permanently elevated by cardiac-specific
overexpression of a modified, phosphatase-deficient 6-phosphofructo-2-kinase/fructose2, 6-bisphosphatase (PFK-2) in transgenic mice. PFK-2 controls the level offructose-2,
6-bisphosphate (Fru-2, 6-P2), an important regulator of phosphofructokinase and
glycolysis. These transgenic mice were used to test two hypotheses: (1) Long term
elevation of cardiac Fru-2, 6-P2 will increase glycolysis and alter glucose oxidation. (2)
Chronically increased cardiac glycolysis will be detrimental to the heart.
To test these hypotheses the following specific aims were carried out:
Specific Aim 1: Produce transgenic mice with overexpression of phosphatase-deficient 6phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK-2).
Specific Aim 2: Compare metabolites and glucose metabolism in transgenic and control
samples using whole hearts, Langendorff perfused hearts and cultured adult
cardiomyocytes.
Specific Aim 3: Assess whether chronically increased glycolysis promotes cardiac
fibrosis, hypertrophy or function.
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METHODS AND MATERIALS

Animals
The bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase
(PFK2) controls levels ofF-2,6-P 2 by catalyzing two opposing reactions: Fru6P + ATP
-)- Fru-2,6-P2 + ADP and Fru-2,6-P2 -)- F6P + Pi. The development of the kinase
activeibisphosphatase deficient PFK2 mutant has been previously described (38,86).
Cardiac specific expression was obtained by ligating a 1.6 kb KpnIlHindIII fragment of
kinase active liver PFK2 (86) behind the a-myosin heavy chain (MHC) promoter(22).
The transgene was designated Mk (for the MHC promoter and the kinase active PFK2
gene). Transgenic mice were produced on a FVB background and maintained as
heterozygotes by breeding to FVB mice. Standard embryo microinjection procedures
were used for producing transgenic animals. All procedures conformed to the Guide for

the Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and were approved by the USDA
certified.

PFK-2 Expression Analysis
PFK-2 protein was analyzed by western blot analysis as previously reported (17). In
brief, PFK-2 was extracted from fresh hearts by homogenization in buffer containing 20
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mM N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES), 1 mM
dithiothreitol, 100 mM KCl, 5 mM Ethylenediaminetetraacetic acid (EDTA), 5 mM
Ethylene

glycol-bis(~-aminoethyl

ether)-N,N,N',N'-tetraacetic acid (EGTA) (pH 7.8), 1.2

mM phenylmethylsulfonyl fluoride, 2.5 mg/liter leupeptin. After precipitation with 40%
PEG, the pellet was dissolved in buffer containing 20 mM TES, 1 mM dithiothreitol, 100
mM KCl, 0.1 mM EDTA (pH 7.5), 0.5 mM phenylmethylsulfonyl fluoride, 2.5 mg/liter
leupeptin. The concentration of extracted protein was measured by the BCA method
(Pierce Chemical Co.). Equal amounts of extracted protein (100 Ilg) were used for
Western blots. Rabbit anti-rat liver PFK-2 serum was used as primary antibody at a
1: 1,000 dilution. Bands were visualized using horseradish peroxidase-conjugated goat
anti-rabbit secondary antibody and enhanced luminol-based chemiluminescent (ECL).
(Amersham Life Science, Buckinghamshire, UK)

Measurement of Metabolites

For the assay ofG6P, F6P and Fru-l,6-P 2, hearts were homogenized in 1 Mice-cold
perchloric acid and centrifuged. The supernatants were neutralized with 2 M KHC0 3 .
The supernatant from neutralized tissue extracts was used for estimation of these
metabolites by fluorometric method (45) .
Cardiac F-2,6-P2 was extracted from fresh heart tissue in 10-20 volumes of 50 mM
NaOH and kept at 80°C for 5 minutes. The extract was cooled and neutralized at O°C by
the addition of ice-cold 1 M acetic acid in the presence of 20 mM HEPES. After
centrifugation at 8,000g for 10 minutes, supernatant was collected and assayed for Fru2,6-P2 by the PFK-l activation method(80). For the assay of Fru-2, 6-P2 , the buffer
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containing pHS.O 100mM TES, 6mM MgCh, 1mM EDTA, O.lmM Dithiothreitol (OTT),
0.22mM

~-Nicotinamide

adenine dinucleotide (NADH), 100mM F-6-P, 10mg/mi

PPi:PFK-1, aldolase, Glycero-3-phosphate Dehydrogenase (GDH), Triosephosphate
isomerase (TIM). The reaction mixtures were kept at 30°C for 10 min, then read by
spectrophotometer at 340nm wave length.
For the assay of glycogen snap frozen tissue was weighed, homogenized in 9 vol. of
30% KOH at O°C and then heated at 70°C for 30 min. The glycogen was precipitated
with absolute alcohol and saturated sodium sulfate and re-dissolved in 0.1 M acetate
buffer, pH 4.7. Then 10 III of homogenate glycogen was hydrolyzed to glucose by the
addition of 50 ng amyloglucosidase (Boehringer-Mannheim) in 100 III of O.l M acetate
buffer. Glucose was then measured by fluorometric assay using hexokinase and glucose6-phosphate dehydrogenase as we reported earlier (42).

Cardiac Perfusion
Langendorffperfusions were carried out as we previously described (41,42). The
heart was rapidly canulated through the aorta and retrogradely perfused at 2 mllmin with
Krebs-Henseleit buffer (KH) consisting of 120 mM NaCl, 20 mM NaHC0 3 , 4.6 mM
KCI, 1.2 mM KH2P04, 1.2 mM MgCh, 1.25 mM CaCh, 5 mM glucose. Throughout the
perfusion KH buffer was continuously equilibrated with 95% 0 2/5% CO 2 which
maintained a pH of 7.4 and temperature was maintained at 37°C. The heart was paced
throughout the procedure at 6 Hz (6 V, 3 ms). Perfusion pressure and contractility was
monitored continuously during the perfusion, as described previously (41, 42).
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Measurements of glycolysis, palmitate oxidation and lactate production in perfused
hearts
Glycolysis was measured using [5- 3H]glucose as the substrate as we have previously
reported (7). For studying the effect of insulin, baseline glycolysis was determined for the
first 30 min followed by 50 min in the presence of 200 f.lU/ml insulin. Glycolysis in the
presence of palmitate was measured by bringing the perfusate to O.4mM palmitate (7) by
addition of 1/20th volume of 8mM palmitate bound to 10% Albumin from bovine serum
(BSA) in KH buffer.
Lactate production and glycolysis measurement with 5}H-glucose were performed
with perfusion buffer containing 5 mM glucose as previously described (17). Palmitate
oxidation was measured by perfusion with 5 mM glucose plus 0.4 mM palmitate
containing 0.75 /lei per ml [9, lO}H] palmitate. Tritiated water produced from tritiated
glucose or palmitate during cardiac perfusion was measured by diffusion and scintillation
counting. Effluent from each time point of the perfusion was assayed in duplicate. For
each experiment, background counts were determined by performing the same
equilibration on perfusion buffer that had not passed through the heart. Diffusion
efficiency was measured in each experiment using tritiated water. Lactate concentration
was measured in 6-fold diluted effluent using Eaton Bioscience Inc. Kit-11112.
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Culture of adult mouse cardiac myocytes

Cardiomyocytes from adult mouse hearts were isolated and cultured by modification
of a previously published protocol (56). Briefly, mice were anesthetized with isofluorane
and injected with heparin (1.7 IU/g body weight). The heart was rapidly removed and
perfused through the ascending aorta for 4 min with perfusion buffer (120 mM NaCl, 15
mM KCI, 0.6mM KH 2 P04 , 0.6mM NaH 2 P0 4 , 1.2mM MgS0 4 , lOmM HEPES, 30mM
Taurine, lOmM 2,3-butanedione monoxime, and 5.5mM glucose, pH 6.95). After 4 min,
the perfusion was switched to perfusion buffer supplemented with collagenase II
500U/ml perfusion buffer (Worthington, NJ) )for 8-11 minutes. The ventricles were then
teased into 10-12 small pieces in stop buffer (perfusion buffer with 10% bovine calf
serum and 12.5f..lM calcium) and transferred to a 15ml conical tube. Tissue was further
dissociated by pipetting and myocytes were allowed to sediment by gravity for 10
minutes. After removal of supernatant, the pellet was carefully suspended in stop buffer.
Calcium was reintroduced in three steps at room temperature to reach a final
concentration of 1.2 mM. Isolated ventricular myocytes were plated at a density of 50
rod-shaped myocytes per square millimeter on laminin-coated cover slips in 10cm2
culture tubes (TPP, Switzerland) containing plating medium (MEM, 10% bovine calf
serum, 10mM 2,3-butanedione monoxime, 100Units/ml penicillin, 2mM glutamine and
2mM NaATP), in 2% CO2 , 37°C. Following 1 hr incubation, the plating medium was
removed and washed once. Myocytes were incubated in 2% CO 2 , 37°C overnight in
culture medium (MEM containing 10 ug/ml BSA, 1 unit/ml penicillin and 20 urn
glutamine with or without 0.4 mM palmitate prebound to 30% fatty acid-free BSA).
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Measurement of glycolysis and glucose oxidation in cardiacmyocytes

After 24 hours culture, medium was replaced with new medium containing [53H]glucose (0.25 ~Ci/ml) and [U-14C]glucose(0.15~Ci/ml) in a final volume of2 m!. For
the no palmitate group, both the old culture medium and assay culture medium did not
contain palmitate. For the 2 hour palmitate group, overnight culture medium did not
contain palmitate and assay culture medium contained 0.4 mM palmitate. For 24 hour
palmitate group, culture medium containing 0.4 mM palmitate and assay culture medium
did not contain palmitate. For 24 plus 2 hour palmitate group, all culture medium
contained O.4mM palmitate. The culture tube was sealed with a rubber stopper and a
plastic central well with a cellulose filter paper and incubated at 37°C for 2 hours. After
the 2 hr assay incubation, the reaction was stopped by the injection of 70% perchloric
acid (0.2 ml), which also liberates 14C02 dissolved in the cultured medium. 0.1 ml of 1M
NaOH was injected into the central well containing filter paper for measuring glucose
oxidation by quantitative collection of 14C02 released. The culture tube was held at room
temperature overnight and the central well filter paper was taken for scintillation
counting. Glycolysis was determined by measuring the production of 3H 20 from the [53H]glucose added to the media as previously described (82). The values determined for
glycolysis and glucose oxidation were normalized to the number of cardiomyocytes to
yield units of nmollminlcardiomyocyte.
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Measurement of Fru-2, 6-P 2 and Fru-1,6-P2 in adult mouse cardiomyocytes

For the assay of Fru-2, 6-P2 , cardiomyocytes cultured for 24 hours were collected in
50mM NaOH (80 ul) and kept at 80 DC for 5 min. The cells were cooled and neutralized
at 4 DC by the addition of ice-cold 1 M acetic acid in the presence of20 mM HEPES.
After centrifugation at 8,000 g for 10 min, the supernatant was collected and assayed for
Fru-2, 6-P2 by the PFK-1 activation method (80). For the assay of Fru-2, 6-P2 , the buffer
containing pH8.0 IOOmM TES, 6mM MgCh, 1mM EDTA, O.1mM DTT, 0.22mM
NADH, 100mM F-6-P, lOmg/ml PPi:PFK-1, aldolase, Glycero-3-phosphate
Dehydrogenase (GDH) and Triosephosphate isomerase (TIM). The reaction mixtures
were kept at 30°C for 10 min, then read by spectrophotometer at 340nm wave length. For
the assay ofFru-1, 6-P2,cardiomyocytes were collected in 1M ice-cold perchloric acid
(0.1 ml) and centrifuged. The assay was run as previously described (82).

Active and Total PDC measurement in adult mouse cardiomyocytes

Active PDH was measured as described essentially as described (92). After overnight
culture medium was removed and cardiomyocytes in the flask/tube were inserted quickly
into liquid nitrogen. Cells were collected in homogenization buffer (0.25 ml) containing
50 mM Hepes, pH 7.5, 0.2 mM KCl, 5 mM dithiothreitol, 0.1 mM Na-p-tosly-L-lysine
chloromethyl ketone, 0.1 mmolll trypsin inhibitor, 0.02 IU/ml aprotinin, 2% rat serum,
and 0.25% (v/v) Triton X-lOO; then sonicated forlO seconds by using 10% duty cycle and
output control of 1 (Branson sonitier 450). Twenty 111 of cell extracts and 20 ul of
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reaction buffer (50 mM Hepes, pH 7.5,1 mM MgCh, 3 mM NAD, 0.4 mM thiamine
pyrophosphate, 0.4 mM CoA, 2 mM dithiothreitol, 0.1% TritonX-100, 7.5 D/ml
lipoamide dehydrogenase, 1 mM pyruvate, and [1_14C] pyruvate (5 /lCi/500ul) were
added to a plastic cup in a 20 ml scintillation vials sealed with a rubber stopper attached
to a plastic central well with a cellulose filter paper soaked in 1 N NaOH (0.1 ml) for
collecting 14C02 . The scintillation vials were incubated at 37°C for 20 min, the reaction
was stopped by injecting 100 111 of 70% perchloric acid. After incubating at room
temperature overnight, the central wells containing filter papers were taken for
scintillation counting. Activity in pmollmin was normalized to cell number.
Total PDC activity was measured as described by Liu et al. (87). Mg2+ and Ca2+in this
method were used to activate the intrinsic cardiomyocyte pyruvate dehydrogenase
phosphatase activity which converts inactive PDC into active PDC (87, 92). For total
PDC measurement 45 ul of cell extract from the above preparation were mixed and
incubated with 5 ul buffer containing 1 mM CaCh, 1 mM of MgCh, and 5 mM
dicholoroacetate at 30°C for 30 min. The method for measuring total PDC activity was
the same as used for measuring active PDC as described above.

Active and Total PDC measurement in adult mouse hearts

Mice were heparinized and anesthetized with isofluorane (3%). Hearts were rapidly
cut from the vena cava and freeze-clamped in aluminum blocks pre-cooled in liquid
nitrogen. Frozen myocardium was powdered under liquid nitrogen and half of the
myocardium powder was used to measure PDC activity and half used for Western blot.
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For analysis of the PDC activity, myocardium powder was homogenized for 10 seconds
in 10 volumes of homogenization buffer using a 10% duty cycle and output control of 1
with a Branson sonifier 450. After centrifugation at 10,000 g, 4°C for 10 min, the
supernatant was collected and assayed for active and total PDC activity as above
described. PDC activity was normalized to protein content.

Isolation of mitochondria

Fresh heart tissue was excised and homogenized by a motor driven Teflon pestle
(Wheaton scientific) in isolation buffer containing 220mM mannitol, 70 mM sucrose and
5mM MOPS, pH 7.4. The homogenate was centrifuged at 700g, 4°C for 10 min. The
supernatant was moved to a new tube for centrifuging at 10,000 x g at 4°C for 10 min.
The mitochondrial pellet was collected and washed again with isolation buffer.

Western blotting

Five or ten llg of total protein from freeze-clamped heart, celllysates and
mitochondrial protein were homogenized with lysis buffer containing 50 mmollL TrisHCl (pH 7.5), 5 mmol/L EDTA, 10 mmollL EGTA, 10 Ilg/mL aprotinin, 10 llg/mL
leupeptin, 10 Ilg/mL pepstatin A, and 50 Ilg/mL phenylmethylsulfonyl fluoride. Tissue
proteins were collected by centrifuging at 12,000 rpm at 4°C for 10 minutes. The protein
concentration was determined, and the sample was then mixed with loading buffer (40

18

mmollL Tris-HCl, pH 6.8, 1% SDS, 50 mmol/L dithiothreitol, 7.5% glycerol, 0.003%
bromophenol blue) and heated at 95°C for 5 minutes and then subjected to electrophoresis
on Bis-Tris 4-12% gels (Invitrogen) at 120 V. After electrophoresis of the gel, the
proteins were transferred to a nitrocellulose membrane in transfer buffer containing 20
mmol/L Tris, 152 mmollL glycine, and 20% methanol. The membranes were rinsed
briefly in PBS and blocked in blocking buffer (5% milk and 0.5% BSA) at room
temperature for 2 hours. The primary antibodies used were anti-PDH-Ela (pSer232)
rabbit pAb (Calbiochem), PDH-Ela (pSer293) rabbit pAb (Calbiochem), PDH-Ela
(pSer300) rabbit pAb (Calbiochem), PDH-Ela (E-23) rabbit polyclonal IgG (Santa Cruz
Biotechnology), MCT2 (M-17) goat polyclonal IgG (Santa Cruz Biotechnology). The
membranes were incubated with primary antibody overnight. On the second day,
membranes were then washed 3 times with TBS-T containing 0.05% Tween-20 and
reacted with secondary antibody for 1 hour. Antigen-antibody complexes were visualized
by chemiluminescent signal using ECL (Amersham GE healthcare) and quantified using
TotalLab TL 100. Actin expression was used as a control. After detection, the membranes
were stripped with stripping buffer (50 mmollL Tris-HCl, pH 7.4, with 150 mmollL N aCl
and 0.1 % B-mercaptoethanol) for 1 hour at room temperature.

Malate and Oxaloacetate measurement in adult mouse whole hearts

Hearts from transgenic and control groups were freeze-clamped. Frozen myocardium
was powdered under liquid nitrogen and homogenized for 30 second in 2 volumes of ice-

19

cold 1M percholoric acid. The extract was centrifuged at 13,000 g, 4°C for 15 min. The
supernatant was collected and was neutralized by the addition of 2M KHC03 (1.05
volumes ofpercholoric acid). After centrifugation at 13,000 g, 4°C for 10 min, the
supernatant was collected and assayed for malate and oxaloacetate (45). For the malate
assay, buffer consisted of 50mM 2-amino-2-methylpropanol buffer pH 9.9, 200uM
NAD+, pH 9.9, 10mM glutamic acid, 3.5u/ml malate dehydrogenase, 0.411/ml aspartate
transaminase. The reaction mixtures were kept at room temperature for 5 min, then read
by spectrophotometer at 340nm. For the oxaloacetate assay buffer of 50mM Tris-HCL
buffer pH 8.1, 50mM NADH, 0.07u/ml malate dehydrogenase was used. The reaction
mixtures were kept at room temperature for 5 min, then read by spectrophotometer at 340
nm wave length.

Murine in vivo myocardial ischemia-reperfusion and infarct size determination

Male FVB and Mk mice were subjected to in vivo left coronary artery occlusion and
reperfusion as described previously(25, 30-33). Briefly, mice were anesthetized with
intraperitoneal injections ofketamine hydrochloride (50 mg/kg) and sodium pentobarbital
(50 mg/kg). The animals were then attached to a surgical board with their ventral side up.
The mice were orally intubated with polyethylene (PE)-90 tubing connected to a Hugo
Sachs mouse ventilator. The tidal volume and respiratory rate were set for each mouse
based on body weight and according to standard mammalian allometric equations. The
mice were supplemented with 100% oxygen via the ventilator side port. Throughout
anesthesia, body temperature was monitored with a rectal thermometer and held constant
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between 36-37 degrees Celsius with an infrared heating lamp. A median sternotomy was
performed using an electric cautery, and the proximal left main coronary artery was
visualized and completely occluded for 40 minutes with 7-0 silk suture mounted on a
tapered needle (BV-l, Ethicon).
At 24 h of reperfusion, the mice were anesthetized as described previously, intubated,
and connected to a mouse ventilator. A catheter (PE-I 0 tubing) was placed in the
common carotid artery for Evans blue dye injection. A median sternotomy was
performed, and the left main coronary artery was re-ligated in the same location as
before. Evans blue dye

(~1.2

ml of a 2% solution) was injected into the carotid artery

catheter into the heart to delineate the ischemic zone from the nonischemic zone. The
heart was rapidly excised and serially sectioned perpendicular to the long axis in I-mmthick sections, which were then incubated in 1.0% 2,3,5-triphenyltetrazolium chloride for
five minutes at 37°C to demarcate the viable and nonviable myocardium within the risk
zone. Each of the five I-mm-thick myocardial slices was weighed. A blinded observer
assessed the areas of infarct, risk, and nonischemic zone using computer-assisted
planimetry (Image J, version 1.38x). All of the procedures for area at risk (AAR) and
infarct size determination have been previously described (30-33).

Cardiomyocyte responses to hypoxia

Cardiomyocytes were isolated, and myocyte contractility was measured as previously
described (90). For the oxygenated assay, myocytes were placed in an open chamber at
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22°C in HEPES-buffered KH buffer [135 mM NaCl, 4 mM KCl, 1 mM MgCh, 10 mM
HEPES, 0.33 mM NaH2P04, 10 mM glucose, 10 mM 2,3-butanedione monoxime
(BDM), and 1.2 mM eaCh; pH 7.4] for 2 h. BDM was included in the contractility assay
buffer because it preserves rod-shaped myocytes during metabolic inhibition (37). We
(89)have previously described the use ofBDM during hypoxic assays of myocyte
contractility. For hypoxia, cardiomyocytes were perfused in the same buffer saturated
with N2 for 15 min and maintained and assayed in a sealed chamber for 2 h at 22°C.
Myocytes were stimulated at 1 Hz using platinum electrodes attached to the chamber.
The mechanical properties of ventricular myocytes were assessed using a video-based
edge detection system (lonOptix, Milton, MA) as previously described (90). Cell
shortening and re-lengthening were assessed using the following indexes: peak
shortening, time to 90% re-lengthening, and maximal velocities of shortening and relengthening (±dL/dt).

Histological Study

Collagen accumulation in the heart sections was determined as described previously
(2). Five J.lm heart sections were placed on slides, deparaffinized, and incubated with a
saturated solution of picric acid containing 0.1 % Sirius Red for staining collagen and
0.1 % Fast Green which stains noncollagen proteins. Sections were kept in the dark and
incubated for 30 min. They were then rinsed with distilled water, dehydrated and
mounted with permount. The sections were visualized, photographed and the interstitial
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fibrosis was quantified by a blind observer using a scale of 0-2 based on the severity of
the collagen accumulation, as we previously described (17). The section was given a
score of 0 for mild accumulation, 1 for moderate accumulation, and 2 for severe
accumulation.

Quantitative RT-PCR

RNA expression of cardiac pathological markers brain natriuretic peptide (BNP) and
B-MHC was measured by real-time quantitative PCR using an ABI 7300 instrument
(Applied Biosystems, Foster City, CA) with a modified protocol (9). In brief, total RNA
was purified from the frozen heart and reverse transcribed to cDNA. RNA-derived
cDNA (10 ng) was mixed with Taqman universal PCR Master Mix and the appropriate
primers and probe and run at 50°C for 2 min, 95°C for 10 min, and 95°C for 15 s
followed by 60°C for 1 min for 40 cycles. The assay identification numbers for the
specific primers and probe of each gene were Mm01255779_gl for BNP and
Mm00600555_ml for B-MHC (Applied Biosystems). The results for B-MHC and BNP
were nonnalized to ND4 mRNA level.
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Statistical analysis

Two factor comparisons were analyzed by two-way ANOVA and Student NewmanKeuls post hoc test. Single comparisons were performed by paired or unpaired Student's
t-test. The accepted level of significance was 0.05. Statistical analyses were performed
with the program Sigma Stat.
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RESULTS

Transgenic lines

Transgenic mice were generated with the transgene Mk, which contained a kinaseactivelbisphosphatase deficient mutant ofliver PFK-2 (85) regulated by the cardiac
specific

~-MHC

promoter (22). Six lines ofMk transgenic mice were generated on a

FVB background and were designated as lines Mkl to Mk6. The founders of lines 1, 2, 4,
and 5 produced litters. Western blots with antibody made against liver PFK-2 (Fig. 4)
demonstrated obvious overexpression of the trans gene in Mk mouse hearts. To confirm
the increase in PFK-2 activity, we measured the level of Fru-2, 6-P2 in transgenic and
control hearts. Cardiac Fru-2, 6-P2 was elevated by three- to fourfold in all transgenic
lines (Fig. 5). Mkl and Mk2 mice were produced first and had indistinguishable
phenotypes for gene expression and Fru-2, 6-P 2 1evels, and they were used
interchangeably in experiments concerning phenotype.
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Cardiac metabolite concentrations

By modifying PFK activity, the Mk transgene is expected to alter the concentration of
metabolites of the glycolytic pathway. Levels of several metabolites were measured in
flash-frozen hearts from FVB and Mk transgenic mice that had been fasted for 3 h. Table
1 shows these results. G6P was reduced by ~ 1.6 fold in Mk transgenic hearts. Coincident
with the reduction in G6P levels, glycogen was decreased by more than eightfold in Mk
hearts. Two metabolites downstream of PFK, Fru-l, 6-P2 and pyruvate, were increased in
concentration; however, the increase did not reach statistical significance. Fru-l,6-P2 was
measured as the combined pool of Fru-l ,6-P2, dihydroxyacetone phosphate, and
glyceraldehyde-3-phosphate since these metabolites are in equilibrium and are most
accurately measured together (45).

Effect of kinase-active PFK-2 on cardiac metabolism

The effect of the Mk trans gene on glycolysis was assessed in Langendroff-perfused
hearts by measuring the metabolism of 5-tritiated glucose. The release of tritiated water
measures the glycolytic steps through the triose phosphate isomerase reaction. The
amount of lactate produced during the perfusion was also measured. As shown in Figure
6, in both the presence and absence of palmitate, the release of tritiated water and lactate
were significantly elevated in Mk transgenic hearts compared with control hearts. The
Mk effect on glycolysis was evident both before and after the addition of insulin. The
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increase in glycolysis did not appear to be related to contractility or perfusion pressure
since no significant differences were observed for contractility between transgenic and
control hearts at any time point (data not shown). Also, in both groups, the perfusion
pressure averaged 65 mm Hg while the flow rate was maintained at 2 mllmin.

To

determine if the trans gene altered the effect of palmitate and insulin, the results for
tritiated water release were replotted in Figure 5. Before the addition of insulin, we found
palmitate to be a more potent inhibitor of glycolysis in FVB mice (55% inhibition) than
in Mk mice (18% inhibition). In the presence of insulin, palmitate did not reduce
glycolysis in FVB or Mk hearts. Our laboratory (17) has previously reported that a
transgene that reduced cardiac Fru-2, 6-P2 blunted the insulin response in perfused hearts.
However, the present study (Figure 7, C and D) failed to support the converse: compared
with FVB hearts, there was no increase in the insulin response in Mk hearts with
increased Fru-2, 6-P2 . In the absence of palmitate, insulin increased glycolysis by 39%
and 31 %, respectively, in FVB and Mk hearts. In the presence of palmitate, the insulin
response was markedly increased, by 230% of basal in FVB mice and by 93% of basal in
Mk hearts. The very large insulin response in palmitate-perfused FVB hearts was due
primarily to the potent inhibition of basal glycolysis by palmitate (Fig. 7A), which was
eliminated by the addition of insulin. Folmes et al. (20) have also reported that insulin has
a greater effect on glycolysis in the presence of palmitate. In addition to the Mk-induced
increase in glycolysis, we found a 30-50% significant reduction in palmitate oxidation in
Mk hearts that was true throughout the duration of the perfusion (Fig. 8A). Insulin
produced a significant reduction (P =0.01 by paired t-test) in palmitate oxidation in both
FVB and Mk hearts. The average decrease produced by insulin was 32 ±1 % and 42 ± 6%
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for FVB and Mk hearts, respectively (Fig. 8B), which was not significantly different in
the two types of hearts (FVB vs. Mk, P = 0.13).

Efficacy of the Mk trans gene in cultured cardiomyocytes

To confirm that the Mk transgene in cultured cardiomyocytes retained the activity we
found in whole heart, the products ofPFK1 and PFK2 were measured. As shown in
Figure 9 and Figure 10, Fru-2, 6-P2 was 2.8 fold higher in Mk myocytes compared to
FVB myocytes and Fru-1, 6-P2 was increased by 1.7 fold. This demonstrates that the
trans gene was still effective in 24 hr cultured cardiomyocytes.

Glycolysis, glucose oxidation and effect of palmitate on glycolysis and glucose
oxidation in cultured adult mouse cardiac myocytes

Glycolysis and glucose oxidation were measured in cardiomyocytes to test the effect
of elevated Fru 2,6P 2 on cardiomycoyte metabolism and to assess how it interacted with
the effect of palmitate. Figure 11 shows the results for glycolysis. Mk myocytes had
significantly higher rates of glycolysis than FVB myocytes in the presence or absence of
palmitate and palmitate had similar inhibitory effects on glycolysis in transgenic and
control myocytes. To reduce glycolysis required the 24 hour pre-assay exposure to
palmitate, no inhibition was seen if palmitate was present only during the 2 hour assay.
Figure 12 shows the glucose oxidation rates measured in the same myocyte cultures. Mk
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myocytes had higher rates of glucose oxidation than FVB myocytes except under the No
Palmitate condition when palmitate was absent before and during the oxidation assay.
Palmitate inhibited glucose oxidation in transgenic and control myocytes under all
treatement conditions. Unlike glycolysis, palmitate inhibited glucose oxidation even if it
was not present during the 24 hr culture period.

PDC activity in Mk hearts and cardiomyocytes

Pyruvate dehydrogenase complex (PDC) activity is generally rate limiting for
mitochondrial glucose oxidation. PDC activity was measured to determine if it could
account for the increase found in cardiomyocyte glucose oxidation. Unexpectedly, both
active PDC (PDCa) and total PDC activity (PDCt) were significantly (P<O.OI) reduced in
Mk compared to FVB cardiomyocytes (Figure 13). Mk PDCa activity was reduced by
59% without palmitate and 37% with palmitate. Mk PDCt activity was reduced by 46%
without palmitate and 52% with palmitate.

To be sure that the Mk decrease in PDCa and PDCt activity was not an artifact of
cardiomyocytes isolation or culture conditions, PDCa and PDCt was measured in whole
hearts. As shown in Figure 14 PDCa activity and PDCt activity were significantly
(P<O.OI) reduced in Mk transgenic hearts compared to FVB hearts. The magnitude of the
whole heart Mk reduction was approximately 20% for PDCa and PDCt.
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PDC E 1a in cardiomyocytes and whole hearts

Western blots were used to measure the amount and phosphorylation state of PDC
subunit Eia (Figure 15A) in cardiomyocytes. Consistent with the reduction PDCt
activity, the abundance ofPDC E1a was reduced by 52% in Mk cardiomyocytes. The
activity of PDC is acutely controlled by reversible phosphorylation of 3 serine residues
on the E 1a subunit. Western blots using antibodies specific for different phosphorylation
sites on PDC E 1a revealed a two-fold increase in E 1a PSer 293 but no apparent change
in the levels ofEla PSer 232 or PSer 300. However, when levels of phosphorylated
forms ofPDC E1a were normalized to total Eia protein both PSer 293 and PSer 300
were significantly increased compared to FVB (Figure 15C).
Western blots of whole heart protein produced similar, though more modest
differences between Mk and FVB samples (Figure 16). In Mk heart E1a protein was
significantly reduced and E1a PSer 293 was significantly increased. Normalized to the
amount ofEla content, PSer 293 and PSer 232 were significantly elevated in Mk heart.

Alternative pathways for glucose oxidation

Elevated glucose oxidation despite reduced PDC activity indicated that Mk myocytes
must have other means for entry of glycolytic products into the mitochondria and citric
acid cycle. One proposed mechanism, independent of PDC, for lactate or pyruvate entry
into mitochondria is via the moncarboxylate transporter (MCT). MCTs have been
identified on mitochondria of many tissues including heart (12, 24). Our unpublished
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gene array comparison of Mk and FVB hearts revealed a 70% increase in MCT2
expression. Based on this suggestive data we isolated mitochondria from Mk and FVB
hearts and performed a Western blot for MCT2 (Figure 17). The level of MCT-2 in Mk
mitochondria was significantly increased by 2.15 fold over FVB cardiac mitochondria.
Multiple anaplerotic pathways exist for glucose oxidation including conversion of
pyruvate to malate via malic enzyme and conversion of pyruvate to oxaloacetate via
pyruvate carboxylase. As shown in Figure 18 malate content was significantly increased
by 84% in Mk hearts, whereas oxaloacetate was the same in FVB and Mk hearts (Figure
19). Since Pound et aI., (65) showed that malate is increased in hearts with elevated
anaplerosis via malic enzyme our results are at least suggestive of increased analplerosis
via malate in Mk hearts.

Myocyte Contractility in Hypoxia

To determine the effect of increased glycolysis on cardiomyocyte contractility and
response to hypoxia in Mk transgenic hearts, myocytes were isolated from Mk and FVB
hearts and incubated with oxygenated or nitrogen bubbled Krebs buffer. Myocyte
contractility was measured using video based edge detection system and the results are
shown in figure 20. Under normoxic condition there was no significant difference in
contractility between Mk and FVB myocytes, as assessed by ±dlldt and % peak
shortening. However, under hypoxic condition, Mk myocytes showed significantly
increased contractility compared with FVB control myocytes for all three parameters. In
FVB myocytes hypoxia reduced all of the variables of contractility by twenty to over
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thirty percent, but in Mk myotyes hypoxia had a zero to ten percent effect. These results
indicate that the Mk trans gene provided almost complete protection from hypoxiainduced contractile deficits in our culture conditions.

Myocardial infarct size

In order to establish whether the cytoprotective effects associated with Mk
transgenesis in isolated myocytes extended to the in vivo setting, we subjected FVB and
Mk mice to experimental myocardial infarction. As shown in Figure 21, the areas-at-risk
for infarction with respect to the left ventricular size (AARIL V) were not significantly
different between FVB (46.3 +/- 3.3%) and Mk (49.3 +/- 6.3%) groups. Infarct size
expressed relative to the AAR (lNF/AAR) was also not different between FVB (28.7 +/5.1 %) and Mk (26.2 +/- 4.8%). Likewise, the INF expressed relative to the entire LV
(lNF/LV) was not different between FVB (13.5 +/- 2.8%) and Mk (12.8 +/- 2.8%).

Cardiac Hypertrophy in Transgenic Hearts

Despite the fact that the Mk trans gene was beneficial to hypoxic cardiomyocyte
function we noted an increase in cardiac size. We found that heart weight and heart to
body weight ratio were significantly increased by ~ 17% compared to FVB control mice,
whereas body weights were similar between Mk mice and FVB mice (Table 2). To
determine if this corresponded to a change in cardiomyocyte size we also compared
isolated cardiomyocyte length (right column of Table 2), measured using video based
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edge detection. Cardiomyocyte length in Mk transgenic hearts was significantly longer
than that in FVB hearts. The cardiac hypertrophy raised the possibility that elevated
glycolysis was detrimental to the heart. Expression of two markers of cardiac stress,

~

MHC and BNP were unchanged (Figure 22 and 23) and H&E staining (Figure 24) ofMk

hearts appeared normal. However, sirius red staining for fibrosis appeared to be
consistently increased in Mk hearts (Figure 25A) and this was confirmed by semiquantitative analysis (Figure 25B).
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DISCUSSION
Lipid metabolism provides most energy for cardiac contraction but under some
pathological conditions such as hypertrophy and ischemia-reperfusion (2), glucose
metabolism increases. It is not clear whether this increase in glucose metabolism is a
beneficial, adaptive response of the heart or a detrimental, maladaptive response. To
avoid the effect of cardiac pathology investigators have employed overexpression of
glucose transporters in the heart to increase glycolysis. Belke et al (7) found that
overexpression of human GLUT4 inceased glycolysis but this did not increase glucose
oxidation. On the other hand cardiac overexpression of GLUT 1 (43,46) increased both
glycolysis and glucose oxidation.

Mk transgenic mice
In the current experiments, we developed transgenic mice designed to have a specific
and permanent increase in cardiac glycolysis, independent of hypertrophy or ischemia.
Multiple lines of mice were produced with a cardiac specific, bisphosphatase deficient
mutant of the enzyme PFK2, designated trans gene Mk. The trans gene produced a three
to four fold increase in cardiac levels of Fru-2, 6-P2 , which is a potent stimulator ofthe
glycolytic regulatory enzyme, PFKl. In this study, we show multiple effects of the
transgene. It increased glycolysis and glucose oxidation but reduced total and active PDC
activity. Despite depletion of available PDC, coupling between glycolysis and glucose
oxidation was maintained possibly via anaplerosis through malate. The Mk trans gene
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reduced palmitate oxidation, and made glycolysis less susceptible to inhibition by
palmitate. The trans gene markedly improved myocyte contractility during hypoxia, but it
did not alter infarct size in response to ischemia in vivo. Despite some beneficial actions,
the Mk transgene promoted hypertrophy and cardiac fibrosis.
For effects produced by the Mk trans gene to provide relevant information about the
role of Fru-2, 6-P 2 in cardiac pathology, it is important that the increase in Fru-2, 6-P2
concentration in Mk transgenic hearts be similar to the concentrations achieved in known
conditions of cardiac pathology. Pressure over-load hypertrophy induces a 2-6 fold
increase in Fru-2, 6-P2 (6, 51). Anoxia or ischemia results in a 2-3 fold elevation in
cardiac Fru-2, 6-P2 content (49). And stimulation of isolated cardiomyocytes with insulin
produces a 4-fold increase in Fru-2, 6-P2 content (39). Thus the three to four fold
increase in Fru-2, 6-P2 seen in our transgenic mice is similar to the increases produced by
insulin, hypertrophy, anoxia or ischemia in the heart (6,39,49,51)

Mk effects on glycolytic metabolism in vivo

An elevation in Fru-2, 6-P2 levels should stimulate activity ofPFK-l. If this is true,
glycolytic metabolites upstream ofPFK-l should be reduced and metabolites downstream
of PFK-l should be increased in transgenic hearts. Our data showed that the
concentration of Glc-6-P was significantly reduced by 1.6 fold. This reduction was likely
the result of increased disposal of Fru-6-P by greater flux through PFK-l, creating a drain
on G1c-6-P concentrations. Glycogen, the production of which branches offupstream of
PFK-l, was diminished almost nine fold in transgenic hearts. The large magnitude of the
glycogen effect may be due to the fact that Glc-6-P has two roles in the control of

35

glycogen content: Glc-6-P is a substrate for glycogen production and Glc-6-P is a
positive regulator of glycogen synthase (54). In addition the increased PFK-l activity
promotes greater use of glycogen to fuel glycolysis. The expected increase in metabolites
downstream ofPFKl was not as clear as the decrease in upstream metabolites. The
concentrations of Fru-l, 6-P 2 and pyruvate increased 50 - 70 %, but the changes were not
statistically significant. This smaller downstream effect may reflect cardiac adaptation to
increased PFK-l flux. This could be due to greater lactate disposal, as we saw in
perfused transgenic hearts, or to greater mitochondrial oxidation of pyruvate obtained
from glucose (32, 33, 35, 37, 54).
The conversion ofF6P to Fru-I, 6-P2 by PFK is one of the rate-limiting, regulated
steps of cardiac glycolysis. Therefore, we anticipated an increase of glycolytic flux in
perfused Mk hearts. Even in the absence of lipid, glycolytic flux in Langendorff perfused
Mk hearts was consistently 20% higher than in nontransgenic hearts. This was not
secondary to elevated contractility or to altered coronary vascular resistance since we
detected no effect of the trans gene on these variables. The most likely cause was the
increased activity of PFK. These results support a significant role for Fru-2,6-P2 even in
the absence of lipid. The addition of 0.4 mM palmitate to the perfusate produced an
apparent two-fold increase in the impact of the transgene on glycolytic flux. This was
because palmitate depressed glycolysis less in Mk hearts than in FVB control hearts.
Fatty acids inhibit glycolysis in large part by inhibiting PFK via the PFK inhibitors citrate
and ATP. Fru-2, 6-P2 antagonizes this inhibition (27). In addition, we found that
palmitate oxidation was about twofold lower in Mk hearts; consequently, palmitate
perfusion produced less citrate and ATP in Mk hearts than in FVB hearts. Therefore, we
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suggest that a combination of elevated Fru-2, 6-P2 and reduced production of citrate and
A TP minimized the effect of fatty acids to inhibit glycolysis in Mk hearts.

Mk effects on glycolysis and glucose oxidation in cultured cardiomyocytes

To investigate in vitro metabolism changes in Mk mice, primary cultured adult
cardiomyocytes were used. The level of Fru-2,6-P2 was increased by 2.8 fold in Mk
cardiomyocytes compared to FVB myocytes, which was consistent with increased Fru2,6-P2 in Mk whole heart and in concert, the level of Fru-l,6-P2 was also significantly
increased by 73% in Mk cardiomyocytes.
With increased Fru-2, 6-P2, glycolysis in Mk cardiomyocytes increased by 40% in the
both the presence and absence of palmitate and glucose oxidation was significantly
increased by 37%-62% in Mk myocytes in the presence of palmitate. In the absence of
palmitate, glucose oxidation had no significant difference between MK group and FVB
group. The Randle cycle illustrates that there is a competition between glucose and
palmitate for their oxidation. Overexpression of GLUT 1 trans gene (43, 46) increased
glucose oxidation and decreased fatty acid oxidation. Cardiac specific overexpressed
human GLUT4 (7) in mouse led to increase glycolysis but not in glucose or fatty acid
oxidation.

In hypertrophied heart, the coupling of glycolysis and glucose oxidation becomes
disrupted by a not fully delineated mechanism (40). However, increased glycolysis was
coupled with increased glucose oxidation in our Mk cardiomyocytes. We expected an
increase in PDC activity in our Mk transgenic hearts, because PDC, an important
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regulator for glucose oxidation, links glycolysis to TCA cycle by catalyzing the
irreversible oxidative decarboxylation of pyruvate to acetyl-CoA, C02 and NADH.
However, unexpectedly, both active and total PDC activities were decreased. One human
study (23) shows that activity ofPDC was decreased in muscle, heart and liver but was
normal in skin fibroblasts. Furthermore, other studies support the finding of changes of
PDH activity and content. A mild hypertrophied heart induced by five weeks of pressure
overload exhibits a decrease of PDC activity (70) and a failing heart with higher glucose
oxidation and lower fatty acid oxidation induced by 3 weeks of pacing shows a reduction
ofPDH-E2 mRNA and protein, although with normal PDC activity (65). Currently there
are no clear mechanisms to explain the decrease PDC activity. However, an islet study
demonstrated that accumulation oflong chain acyl-CoA can inhibit PDC activity (44). In
Mk hearts, both fatty acid oxidation and NADPH content (data not shown here) were
reduced, suggesting long chain acyl-CoA may be accumulated in Mk heart to inhibit PDC
activity. Metabolic acidosis show pyruvate oxidation in both liver and human skeletal
muscle during exercise by deceasing activity of PDC (26, 77). Reduced PDC activity
results from alterations in the content ofPDC substrates, acetyl-CoA, NADH and H+,
leading to greater relative activity of PDK (26). In our Mk hearts, lactate production was
about 2 fold higher compared to control group, suggesting lactic acidosis may stimulate
PDK activity contributing to decrease of PDC activity by phosphorylation or accelerating
PDH protein degradation. Other factors e.g. HNE (28) and TNF-a (91) could also be
possible reasons involved in the pathogenesis of decreased PDC activity in Mk hearts.
The paradoxical findings between PDC activity and glucose oxidation in these studies
suggested that PDC did not playa primary role or directly relate with alteration of
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glucose oxidation. PDC is responsible for the pyruvate decarboxylation which accounted
for about 42% of citrate. Since entry of pyruvate into the TCA cycle through PDC is
disrupted in Mk hearts, alternative routes for pyruvate influx to the TCA cycle have been
proposed. Isolated perfused heart experiments (62) showed that pyruvate can be
carboxylated to form malate or oxaloacetate (OAA) via malic enzyme or pyruvate
carboxylase (Figure 2). In Mk hearts, malate content increased by 84%, although the
OAA content was not changed between Mk and FVB. MCT-2, a pyruvate and lactate
transporter was increased by about 70% in mRNA level and elevated by 2 fold in protein
level in mitochondria, suggesting an increased flux of pyruvate into the mitochondria for
OAA production through pyruvate carboxylase and an increased flux of malate via malic
enzyme into mitochondria. High rate of citric acid cycle flux with low concentration of
intermediates (55) may explain the lack of change of OAA content despite the increase of
MCT-2 protein in mitochondria. Furthermore, in isolated rat heart, studies show that
malic enzyme but not pyruvate carboxylase predominates in the heart (62). Thus,
elevation of malate content by about 84% in Mk transgenic hearts might indicate a major
anaplerosis pathway for increasing citric acid cycle flux, although both malic enzyme and
PC are constitutive processes in the heart.

Functional and morphological effects of the Mk trans gene

Basal contractility was unchanged in Mk hearts when assayed either during
Langendorff perfusion or in isolated cardiomyocytes. This is consistent with results we
have obtained with two other transgenic models of increased or decreased glycolysis (17,
42). The results from all of these transgenic lines have shown that altering glycolysis for
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many months does not change myocyte contractility when assayed in oxygenated
conditions. During hypoxia, glycolysis becomes more important to myocyte function.
Consistent with this, cultured Mk myocytes were much less susceptible to hypoxia. In
fact, under hypoxic conditions that significantly impaired control myocytes in our assays,
we saw no detectable decline in Mk cardiomyocyte contractility. Resistance to hypoxia is
the opposite of what we previously found in myocytes with impaired glycolytic capacity
(17). This confirms the essential role of glycolysis during hypoxic conditions. However,
isolated myocyte experiments do not allow for extrapolation to in vivo conditions. In

vivo, multiple fuel substrates are available, in contrast to the sole substrate of glucose
used for in vitro myocyte culture. Also, excess lactate (Figure 3) from increased
glycolysis in Mk hearts may accumulate in poorly perfused myocardium of ischemic
intact hearts (68). In addition, fibrosis and hypertrophy in Mk mice could increase cardiac
work during in vivo ischemia, and the reduced glycogen content (Table 1) of Mk hearts
reduced carbohydrate reserves. Therefore, it was not a complete surprise that the
protection from hypoxia in isolated myocytes was not replicated in vivo, where infarct
damage following ischemia- reperfusion was similar in transgenic and control hearts. A
more complete analysis of ischemia resistance in Mk hearts should be undertaken using
low-flow and stop-flow perfusion of isolated hearts to distinguish what components
contribute to resistance to hypoxia of cardiomyocytes in culture but not in vivo.
Despite increased glycolysis by which the Mk trans gene can protect cardiomyocytes
against hypoxia, we found there is an increase in cardiac size. Heart weight, heart weightto-body weight ratio, and cardiomyocyte length were all significantly elevated in Mk
transgenic mice, demonstrating hypertrophy. To test if this mild hypertrophy indicated
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cardiac pathology, we examined two other signs of pathology: upregulation of "fetal state
cardiac genes" (53,54) and induction of fibrosis. There was no significant effect of the
Mk transgene on the expression of~-MHC and BNP. Since these genes are upregulated
by stress, this did not support the conclusion that Mk hearts were undergoing severe
pathological stress (63). On the other hand, we found that cardiac fibrosis was increased,
and fibrosis is a cardiac stress marker (9). Overall, the weight of the evidence, fibrosis
and hypertrophy imply that the Mk transgene induces a mild state of pathology. By
constitutively elevating Fru-2,6-P2, the Mk trans gene chronically elevated glycolysis and
blocked the normal mechanisms controlling carbohydrate usage. The increased glycolysis
of chronic heart failure may ultimately be maladaptive. It is striking that our present
transgene, which elevated Fru-2, 6-P2, and our previous transgene (17), which reduced
Fru-2, 6-P2, both produced mild hypertrophy and fibrosis. This demonstrates the
sensitivity of the heart to disruption of normal metabolic control.

Relevance to diabetic cardiomyopathy
In diabetes the metabolism of the heart becomes much more dependent on fatty acids
and simultaneously the rate of glycolysis and glucose oxidation goes down. This change
in fuel usage may be one of the causes of diabetic cardiomyopathy. Our Mk mice
represent the opposite situation to diabetes: Glycolysis and glucose oxidation are elevated
and fat usage is reduced. Since the Mk mice had mild cardiac pathology this result
suggests that a reversal of diabetic cardiac fuel usage would not necessarily be good for
the heart. Both diabetic cardiomyopathy and Mk cardiac pathology suggest that

41

maintaining the metabolic flexibility of the heart to use the most appropriate or available
fuel substrate is essential to avoiding cardiac dysfunction.

Summary
In summary, we produced mice with chronic and stable elevation of cardiac Fru-2, 6P2 . This resulted in significant changes in cardiac metabolite concentrations, increased
glycolysis and glucose oxidation, reduced palmitate oxidation, elevation of malate
content and decreased PDC activity without uncoupling the glycolysis and glucose
oxidation and protection of isolated myocytes from hypoxia. Increased malate content
suggested that increased anaplerosis pathway in Mk hearts solved the paradoxical finding
between reduced PDC activity and elevated glucose oxidation. This increased anaplerosis
pathway could be associated with the pathological changes of hypertrophy with cardiac
fibrosis in Mk heart. Finally, chronic elevation of glycolysis produced detrimental effects,
suggesting that the elevation of glycolysis in failing hearts could be injurious to an
already compromised heart.
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Figure 1: A balance between glucose and fat consumption exists in the
cardiomyocyte from normal heart. Glucose is transported into cytosol by glucose
transporter I and 4 and provides 30% of energy for heart through glycolysis and glucose
oxidation as shown in the left pathway. Fatty acid is transported into cytosol by
transporters FAT/CD36 etc. for fatty acid oxidation and provides 70% energy for heart as
shown in the right pathway.
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Figure 2: Alternative routes for pyruvate influx from glucose to the citric acid cycle
(anaplerosis). The major route for pyruvate to enter the citric acid cycle is by conversion
to acetyl-CoA by the pyruvate dehydrogenase complex (PDC). There are also two
anaplerotic pathways shown for entry of pyruvate into the citric acid cycle. Cytosolic
pyruvate carboxylation to malate via malic enzyme (ME) or mitochondrial carboxylation
to oxaloacetate via pyruvate carboxylase (PC). MCT -2 can transport pyruvate or lactate
into the mitochondria for further oxidation.
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Lactate diffuses out
to culture medium

Figure 3: Scheme for potential beneficial and detrimental effects of high glycolysis
under myocardial Ischemia.
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Figure 4. Transgenic hearts overexpress 6-phosphofructo-2kinase/fructose-2,6bisphosphatase (PFK-2) protein For the Western blot, cardiac protein was analyzed
using rabbit anti-rat liver PFK-2 antibody. Extracts from 3 Mkl hearts are shown. Similar
results were obtained in all Mk transgenic lines.
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Mk5

Figure 5. Transgenic hearts have elevated fructose-2,6-bisphosphate(Fru-2,6-P z}.
For the measurement of Fru-2, 6-P2, hearts were extracted with 50 mM NaOH and Fru-2,
6-P2 was estimated using pyrophosphate-dependent fructose-6-phosphate 1
phosphotransferase. Transgenic Fru-2, 6-P2 values were significantly higher than those in
FVB hearts (* P < 0.01 by ANOVA). No significant differences were obtained within Mk
groups. The numbers of animals used were 4 FVB, 4 Mkl, 4 Mk2, and 3 Mk5 mice.
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TABLE 1
FVB
Mk

Pvalue

Fru·1,6,Pl
Glc-6·P
Inmollg) Ilnmollg)
225±67
277±93
140±17
356±108
0,01
0,25

Fru·2,6,P l Pyruvate Glycogen
Inmollg)
Inmollg) lumollg)
5,12±O,88 133±44 2,4±1,94
10,4±1.34 227±110 O,27±o,22
0,01
0,15
0,01
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Table 1: Glycolytic intermediates concentration in FVB and Mk hearts. Values
are means ± SE for at least 5 mice in each group after a 3 hr fast. P values were
determined by students t-test. . G6P was reduced by ~ 1.6 fold in Mk transgenic hearts
(p<O.OI). Coincident with the reduction in G6P levels, glycogen was decreased by more
than eightfold in Mk hearts (p<O.Ol). Two metabolites downstream ofPFK, Fru-I, 6-P2
and pyruvate, were increased in concentration; however, the increase did not reach
statistical significance (p=0.25 for Fru-l, 6-P2 and p=O.15 for pyruvate).
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Figure 6: The kinase active PFK-2 transgene increases glycolysis in Langendorff
perfused hearts. A and C: glycolysis (A) and lactate release (C) without palmitate. Band
D: glycolysis (B) and lactate release (D) in the presence of 0.4 mM palmitate. The shaded
box shows the addition of200 uU/ml insulin. Values for FVB and Mk hearts were
compared by two-way ANOVA (* P <0.05).Values are means ± SE for 5 mice/time point.
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Figure 7. Effect of palmitate and insulin on glycolysis in FVB mice and Mk mice.
Preinsulin glycolysis was reduced by 55% (* P < 0.02) in FVB mice (A) but only by 18%
in Mk mice (B; P < 0.24). In the presence of insulin, palmitate did not reduce glycolysis
in FVB or Mk hearts. C and D: insulin elevated glycolysis in FVB (C) and Mk (D) hearts
with or without palmitate (#P < 0.02, preinsulin vs. insulin by paired t-test). The relative
effect of insulin was greater in the presence of palmitate because insulin decreased
palmitate inhibition of glycolysis. n = 5 FVB and 5 Mk hearts. Data are from Fig. 4 at 30
and 80 min.
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Insulin

Figure 8. The Mk transgene reduces palmitate oxidation in Langendorff-perfused
hearts. A: FVB palmitate oxidation values were greater than Mk values at all time points
(P < 0.01 by two-way ANOVA, n

= 5 FVB and 7 Mk hearts). B: effect of insulin on

palmitate oxidation by replotting the 30- and 80-min results from A. Insulin reduced
palmitate oxidation by 32% in FVB hearts and by 42% in Mk hearts (#P <0.01 by paired
t-test).
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Figure 9: Levels of Fru-2, 6-P2 in FVB and Mk cardiomyocytes cultured for 24 hrs.
The

* in both panels indicates that each metabolite is higher in Mk cardiomyocytes

(P<O.OI by t-test). Values are the mean and standard error of the mean (SEM) for at 8 to
12 assays.
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Figure 10: Levels of Fru-l,6-P2 in FVB and Mk cardiomyocytes cultured for 24
hrs. The

* in both panels indicates that each metabolite is higher in Mk cardiomyocytes

(P<O.OI by t-test). Values are the mean and standard error of the mean (SEM) for 12
assays.
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Figure 11: Measurent of glycolysis in Mk and FVB cardiomyocytes. All myocytes
were cultured for 24 hrs and then assayed for metabolism during the next 2 hrs.
Palmitate (O.4mM) was present during the 24 hr culture period and/or the 2 hr assay
period as indicated on the X axis.

* indicates that Mk glycolysis values were

significantly greater than FVB values measured under the same conditions (P<O.OI). #
indicates that for FVB myocytes glycolysis values were significantly lower than values
obtained from FVB myocytes cultured and assayed under the No Palmitate condition
(Panels A). The symbol & indicates that for the different palmitate conditions Mk
glycolysis values were significantly lower than values obtained from Mk myocytes
cultured and assayed under the No Palmitate condition ( P<O.05). The number of animals
used was 7 FVB and 6 Mk. Statistic were performed by two-way ANDVA. Vertical bars
are SEM.
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Figure 12: Measurent of glucose oxidation in Mk and FVB cardiomyocytes. All
myocytes were cultured for 24 hrs and then assayed for metabolism during the next 2 hrs.
Palmitate (O.4mM) was present during the 24 hr culture period and/or the 2 hr assay
period as indicated on the X axis.

* indicates that Mk glucose oxidation values were

significantly greater than FVB values measured under the same conditions (P<O.05). #
indicates that for FVB myocytes glucose oxidation values were significantly lower than
values obtained from FVB myocytes cultured and assayed under the No Palmitate
condition (P<O.Ol). The symbol & indicates that for the different palmitate conditions
Mk glucose oxidation values were significantly lower than values obtained from Mk
myocytes cultured and assayed under the No Palmitate condition (P<O.05). The number
of animals used was 7 FVB and 6 Mk. Statistic were performed by two-way ANOVA.
Vertical bars are SEM.
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poe

Figure 13: Active PDC and Total PDC activity are decreased in Mk transgenic
cardomyocytes. PDC activity was measured after 24hr culture with or without O.4mM
palmitate. Active and total PDC were measured as described in Methods and activity
was normalized to the number of cells in each culture.

* indicates Mk was lower than

FVB for the same assay and culture conditions (P<O.Ol). # indicates that for FVB
myocytes active PDC was lower for the palmitate group then the no palmitate group
(P<O.O 1). The number of animals used was 10 for FVB and 10 for Mk. Statistic were
obtained by two-way ANOVA using Mk and palmitate as factors. Vertical bars are SEM.
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Figure 14: Active PDC and Total PDC activity are decreased in Mk transgenic
hearts. Active and total POC were measured as described in Methods and activity was
normalized to the number of cells in each culture.

* indicates Mk was lower than FVB

for the same assay conditions (P<O.O l). The number of animals used was 4 for FVB and
4 for Mk. Statistics were calculated by t-test. Vertical bars are SEM.
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Figure 15: PDC Ela expression and phosphorylation in Mk transgenic and FVB
control cardiomyocytes. (A) Western blots for the indicated antibodies. Each lane
contains protein from cardiomyocytes isolated from a different Mk or FVB heart. (B)
Densitometric analysis of protein subunit levels normalized to actin and expressed as %
of average FVB. (C) Ratio of each PSer normalized to the amount of PDC E I a for that
sample.

* indicates that Mk was significantly different from FVB for the same variable.

n=5 for FVB and 7 for Mk.
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Figure 16: PDC Ela expresion and phosphorylation in Mk transgenic and FVB
control hearts. (A) Western blots for the indicated antibodies. Each lane contains
protein from a different Mk or FVB freeze clamped heart. (B) Densitometric analysis of
protein subunit levels normalized to actin and expressed as % of average FVB. (C)
Ratio of each PSer normalized to the amount of PDC E 1a for that heart.

* indicates that

Mk was significantly different from FVB for the same variable. n=5 hearts per group.
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Figure 17: Increased amount of MeT-2 in isolated mitochondria from Mk
transgenic hearts. (A) Immunoblots for MCT2 and COXIV loading control: each lane
contains mitochondrial protein from a different heart. Arrows indicate positions of MW
markers MCT2 is 44 kDa and COXIV is 17 kDa. (B) Densitometric analysis of MCT2
normalized to COXIV expressed in % of the average FVB value. *: Mk is significantly
different from FVB (P<O.OI). n=5 hearts per group.
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Figure 18. Malate content in whole heart. Metabolites were measured in perchloric
acid extracts of whole heart as described in Methods.

* indicates that malate content was

significantly elevated in Mk heart. Hearts from 7 Mk mice and 5 FVB mice were
assayed.

82

..,
Q)

•

400.00

T

1>0

.......

.....
0

ec:~ 300.00

~..,

.

..c:

Q)

1>0

.., .; 200. 00
~

Q)

t.l

Ol

.....0

100.00

Ol

><

0

0.00

FVB

Mk

83

Figure 19. Oxaloacetate content in whole heart. Metabolites were measured in
perchloric acid extracts of whole heart as described in Methods. Hearts from 7 Mk mice
and 5 FVB mice were assayed.
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Figure 20: Overexpression of kinase-active PFK-2 improves contractility under
hypoxia. Cardiomyocytes were isolated and incubated under normoxic or hypoxic
conditions. The contractile properties of ventricular myocytes from FVB control and Mk
transgenic mouse hearts was measured by video-based edge detection. Graphs show the.
percentage of shortening under normoxic (A) and hypoxic (B) conditions as well as the
maximal velocities of cell shortening and relengthening (±dL/dt) under normoxia (C) and
hypoxia (D). Values are means _±SE for 60-80 cells from 4 mice/group. *p < 0.02, Mk
vs. FVB by Student's t-test. n=5 hearts per group.
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Figure.21. Myocardial infarct size (INF) was determined after 40 min of in vivo
coronary occlusion and 24 h of reperfusion. The area at risk (AAR) with respect to the
left ventricle (LV) was not significantly different between FVB wild-type and Mk
transgenic mice, indicating consistent execution of the surgical protocol between the two
groups. The amount of nonviable myocardium, according to triphenyltetrazolium
negativity, was also similar between the two groups. This was true whether INF was
expressed relative to the AAR (INF/AAR) or to the entire LV (INF/LV). P = not
significant (NS) for all comparisons. n = 6 mice/group.
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Table
2

sex
FVB
Mk

m
m

age
138 ± 2
131 ± 4

body wt
(gm)
29.9 ± 0.6
29.8 ± 0.6

heart wt
(mg)
132.7 ± 3.3
155.3 ± 2.5*

89

hw/bw
4.44 ± 0.07
5.21 ± 0.08 *

myocyte
length
J.lm
126± 3
151 ±3 *

Table 2. Mk hearts and myocytes are enlarged Values are means ±SE; n = 13 male
Mk mice and 27 male FVB mice. Myocyte length was the average of 52 myocytes from 4
mice/group. *p < 0.001 by Student's t-test.
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Figure 22: Real time-PeR shows no elevation of BNP mRNA in MK transgenic
mice. Values are the mean ±SE for 4 mice per group. Values were not significantly
different by students t-test.
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Figure 23: Real time-peR shows no elevation of p-MHC mRNA in MK transgenic
mice. Values are the mean ±SE for 4 mice per group. Values were not significantly
different by students t-test.
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Figure 24: H&E staining in Mk and FVB hearts. Cardiac morphology was
visualized by H&E staining. The above picture shows representative staining of FVB(3)
and Mk(3) hearts.
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Figure 25: Fibrosis in Mk hearts. Collagen accumulation was visualized by sirius red
staining at x40. A, shows representative staining ofFVB and Mk hearts. B shows average
(± SE) score for sirius red staining from 60 photographs taken from FVB (3) and Mk (3)
mouse hearts. Staining was rated by a blind observer on a scale of 0-2, where 0 indicates
mild, 1 increased and 2 severe interstitial accumulation of collagen. The values shown
are means ± SE and were analyzed by student's t-test (*P < 0.01).
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